MARKET

BLUE

BLUE

bluebird bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

55.67
-0.28
-0.50%
After Hours: 55.67 0 0.00% 19:04 09/24 EDT
OPEN
55.33
PREV CLOSE
55.95
HIGH
56.19
LOW
53.36
VOLUME
678.87K
TURNOVER
--
52 WEEK HIGH
108.15
52 WEEK LOW
38.95
MARKET CAP
3.69B
P/E (TTM)
-4.7331
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Bluebird bio’s Lentiglobin nabs PRIME status in Europe
Bluebird bio's (BLUE) LentiGlobin, an investigational gene therapy (bb1111) for the treatment of sickle cell disease ((SCD)) was granted eligibility to the Priority Medicines ((PRIME)) program by the EMA.PRIME, akin to
Seekingalpha · 1d ago
Bluebird bio’s Lentiglobin nabs accelerated review in Europe for sickle cell
Bluebird bio's (BLUE) LentiGlobin, an investigational gene therapy (bb1111) for the treatment of sickle cell disease ((SCD)), has been granted PRIME status in Europe.PRIME, akin to Breakthrough Therapy status in the
Seekingalpha · 1d ago
bluebird bio’s LentiGlobin™ for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency
bluebird bio, Inc. (Nasdaq: BLUE) announced today that its investigational treatment for sickle cell disease (SCD), LentiGlobin™ for SCD gene therapy (bb1111), was granted eligibility to the Priority Medicines (PRIME) program by the European Medicines Agency (EMA).
Business Wire · 1d ago
Bristol Myers, Bluebird Bio Stocks Up As Blood Cancer Treatment Gets FDA Priority Review
Investor's Business Daily · 2d ago
The Daily Biotech Pulse: Legal Relief For Evolus, Fulgent to Join S&P SmallCap 600, AIM ImmunoTech's Positive Cancer Drug Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 21)
Benzinga · 2d ago
FDA accepts Bristol Myers' application for CAR T therapy for multiple myeloma
Under Priority Review status, the FDA accepts Bristol Myers Squibb's (BMY) marketing application seeking approval of B-cell maturation antigen ((BCMA))-directed CAR T therapy idecabtagene vicleucel (ide-cel; bb2121) for the treatment
Seekingalpha · 2d ago
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)
FDA Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel....
Business Wire · 2d ago
Should I Buy bluebird bio Inc (BLUE)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend
Insider Monkey · 09/10 01:21
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BLUE. Analyze the recent business situations of bluebird bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 23 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BLUE stock price target is 103.67 with a high estimate of 196.00 and a low estimate of 68.00.
EPS
Institutional Holdings
Institutions: 420
Institutional Holdings: 66.43M
% Owned: 100.31%
Shares Outstanding: 66.22M
TypeInstitutionsShares
Increased
120
10.99M
New
109
2.51M
Decreased
52
7.62M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Independent Director
Daniel Lynch
President/Chief Executive Officer/Director
Nick Leschly
Chief Financial Officer
William Baird
Chief Operating Officer/Secretary
Jason Cole
Chief Accounting Officer
Katy Burnett
Chief Scientific Officer
Philip Gregory
Vice President - Finance/Treasurer
Kory Wentworth
Other
David Davidson
Other
Alison Finger
Other
Joanne Smith-Farrell
Director
Denice Torres
Independent Director
John Agwunobi
Independent Director
Wendy Dixon
Independent Director
Douglas Melton
Independent Director
David Schenkein
Independent Director
William Sellers
Independent Director
Mark Vachon
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BLUE
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of bluebird bio Inc stock information, including NASDAQ:BLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLUE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLUE stock methods without spending real money on the virtual paper trading platform.